News and Trends 11 Jul 2022 Study results reveal bleeding episodes are significantly reduced by hemophilia drug People suffering from a severe blood disorder may only have to take a once-monthly drug following successful results from an ongoing study. Global healthcare company, Sanofi, has been conducting a study into fitusiran prophylaxis and results have shown it reduces bleeds by 61 per cent in people with hemophilia A or B, with or without […] July 11, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2022 Sanofi Global Health launches 30 nonprofit medicines in low-income countries Medicines specifically for the world’s most impoverished countries and at-risk populations have been produced and launched by Sanofi. The announcement was made at a global health stakeholders meeting in Paris. The standard of care medicines have formed the Impact brand which includes insulin, glibenclamide and oxaliplatin among others. A secure distribution of 30 Sanofi medicines […] July 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2022 Next-Gen Covid-19 Vaccines and Drugs Crowd into Late-Stage Trials Despite the widespread rollout of vaccines over 2021, the Covid-19 pandemic remains a threat to healthcare systems worldwide. Numerous treatments and vaccines are hitting the late-stage pipeline, which could greatly expand the anti-Covid-19 arsenal. Two years ago, the Covid-19 pandemic swept the world and left economic disruption, healthcare crises, and widespread lockdowns in its wake. […] February 15, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2022 Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to develop oncology and immunology treatments. According to the deal’s terms, the partners will develop up to 15 small molecule drugs to treat cancer and immunological […] January 11, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2020 Kiadis’ Natural Killer Cell Therapies Earn €308M Acquisition by Sanofi The French big pharma Sanofi has offered €308M to acquire the Dutch firm Kiadis Pharma and get hold of cancer cell therapies based on a type of immune cells called natural killer cells. The offer comes not long after Sanofi inked a deal worth up to €857.5M to license a preclinical-stage cancer cell therapy from […] November 3, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 30 Mar 2020 Could mRNA Vaccines Fulfill Their Potential Against Coronavirus? The first vaccine against coronavirus disease could one day be made of mRNA. How is mRNA showing promise against the pandemic, and what could it signify for the mRNA field? The global number of coronavirus disease (Covid-19) cases has passed 600,000 and is threatening to bring healthcare systems worldwide to their knees. To control the […] March 30, 2020 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 25 Feb 2020 Update: Janssen and Maze Jump on Board Finnish Genomics Project Update (25/02/2020): Janssen and the US company Maze Therapeutics are the latest pharma companies to sign up as partners in the public-private genomics collaboration FinnGen. FinnGen’s pharma partners now total 11, including Sanofi and GSK, which joined early last year. Published 23/01/2019: Sanofi and GSK have joined up with a project collecting genomic and health […] February 25, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2019 European Project Launches to Tailor Autoimmune Disease Treatments Public and private organizations across Europe will pool their resources in an €80M project to discover biomarkers that can predict which patients will respond best to treatments for autoimmune diseases. The project is called Taxonomy, Treatments, Targets and Remission, or 3TR for short, and is funded by the EU’s Innovative Medicines Initiative for the next […] October 31, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2019 Sanofi Obtains License for French Company’s Antibody Engineering Platform Sanofi has signed a licensing deal with French biotech Biomunex, whose antibody technology has the potential to develop new immunotherapy treatments for cancer and infectious diseases. Sanofi will give Biomunex an upfront payment, along with further installments upon achieving key development milestones. The amounts have not been disclosed. Biomunex is able to make a wide variety […] January 15, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2019 Sanofi Invests €80M in mRNA Cancer Vaccine Company Sanofi is to make an €80M equity investment in the German biotech BioNTech, and the two have agreed to co-develop a cancer vaccine based on injecting messenger RNA into solid tumors. This agreement is an extension of Sanofi and BioNTech’s collaboration, which began in 2015. The two companies will continue to co-develop and co-commercialize a candidate […] January 7, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 30 May 2018 How to Close a €3.9B Acquisition Deal for Your Biotech Company Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal with Sanofi earlier this month, after details were announced in January. Edwin Moses, CEO of Ablynx, shared the company’s success story with attendees at our recent Refresh Meetup in Brussels. The technology behind Ablynx’s success […] May 30, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 8 Mar 2018 Evotec Takes Over Sanofi’s Infectious Disease Pipeline Evotec will be getting over 10 assets, €60M upfront and about 100 scientists from Sanofi’s infectious disease research unit to work on developing new antimicrobials. Evotec has entered exclusive negotiations with Sanofi to accelerate infectious disease R&D through a new innovation platform located near Lyon, France, that will be open to academia, private companies, foundations and government agencies. Sanofi, […] March 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email